Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Diabetic Ulcers Treatment Market

Diabetic Ulcers Treatment Market Share

Report ID: GMI6078
Published Date: Jun 2023
Report Format: PDF

Download Free Sample

Diabetic Ulcers Treatment Market Share

Major players operating in diabetic ulcers treatment industry include

B. Braun Melsungen AG
Smith & Nephew, Inc.
Organogenesis Holdings Inc.
Derma Sciences Inc.
Integra LifeSciences
Hill Rom Holdings Inc.
Mölnlycke Health Care AB
Coloplast Corp
Cardinal Health
ConvaTec Group Plc
Tissue Regenix
3M Healthcare
Medline Industries, Inc.

These leaders majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of diabetic ulcers treatment reached USD 9.3 billion in 2022 and will grow at over CAGR 5.8% CAGR from 2023 to 2032 attributed to the rise in the diabetic population continues.

The foot ulcer segment dominated the diabetic ulcers treatment market in 2022 with a industry share of 88.8%, owing to high incidence of diabetic foot ulcers amongst diabetic patients.

North America diabetic ulcers treatment industry accounted for over 38.3% revenue share in 2022 and will continue to grow over 2023-2032, due to rising diabetes rate in the region due to factors such as sedentary lifestyles, unhealthy eating habits, and an aging population.

B. Braun Melsungen AG, Smith & Nephew, Inc., Organogenesis Holdings Inc., Derma Sciences Inc., Integra LifeSciences, Hill Rom Holdings Inc., Mölnlycke Health Care AB, Coloplast Corp, Cardinal Health, ConvaTec Group Plc, Tissue Regenix, 3M Healthcare, and Medline Industries, Inc. among others.